First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: Pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials

Young, Rowan D.; Natukunda, Agnes; Litière, Saskia; Woll, Penella J.; Wardelmann, Eva; Graaf, Winette T.A. van der

doi:10.1016/j.ejca.2014.10.004

Cited by 95 publications

(72 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most are diagnostically challenging and lack effective systemic treatments. While conventional cytotoxics do improve survival in Ewing sarcoma, rhabdomyosarcomas, and osteosarcoma, they confer little curative benefit in most soft-tissue sarcomas, as confirmed by a recent analysis of 2,665 cases across 11 clinical trials (1). Much recent effort has gone into targeting expressed proteins in activated oncogenic pathways, but these have had disappointing results in phase II trials (2)(3)(4), and few sarcoma studies have progressed to phase III (5).…”

Section: Introductionmentioning

confidence: 99%

New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype

Lim

Poulin

Nielsen

2015

Clinical Cancer Research

View full text Add to dashboard Cite

There are more than 100 sarcoma subtypes, each uncommon and diagnostically challenging. Conventional chemotherapy has little benefit for most soft-tissue sarcomas; new treatment strategies are needed. Multiple recent genomic studies have provided detailed insights into sarcoma biology, including more accurate classification by molecular subtype, identification of recurrent mutations in oncogenic pathways, and evidence of epigenetic dysregulation. Advances in immunotherapy (adoptive immune cell transfer, tumor vaccine strategies, and immune checkpoint inhibition) have also provided a better understanding of how immuno-oncology might best be applied to sarcoma treatment, including connections to oncogenic pathways that may support combination strategies with conventional and targeted therapies. In this article, we review the latest sarcoma genomic studies and immuno-oncology developments and discuss how the findings suggest potential strategies to improve diagnosis and treatment across multiple sarcoma subtypes.

show abstract

Section: Introductionmentioning

confidence: 99%

New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype

Lim

Poulin

Nielsen

2015

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Agents in this pharmacological group of antineoplastic drugs include doxorubicin, daunorubicin, epirubicin, and idarubicin. They are the backbone for many chemotherapy regimens in the treatment of breast cancer 1, 2 , lymphoma 3–7 , leukaemia 8, 9 and sarcomas 10, 11 . This may be due to the wide range of mechanisms which anthracyclines are thought to act on including: (i) initiation of apoptosis via inhibition of topoisomerase II, (ii) DNA synthesis inhibition, (iii) DNA binding and alkylation, (iv) DNA cross-linking, (v) interference with DNA strand separation and helicase activity, and (vi) free radical formation and lipid peroxidation 12 .…”

Section: Introductionmentioning

confidence: 99%

Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis

Leong

Chaiyakunapruk

Lee

2017

Sci Rep

View full text Add to dashboard Cite

Anthracyclines play an important role in the management of patients with cancer but the development of anthracycline-induced cardiotoxicity (ACT) remains a significant concern for most clinicians. Recently, genetic approach has been used to identify patients at increased risk of ACT. This systematic review assessed the association between genomic markers and ACT. A systematic literature search was performed in Medline, PubMed, Cochrane Central Register of Controlled Studies, CINAHL Plus, AMED, EMBASE and HuGE Navigator from inception until May 2016. Twenty-eight studies examining the association of genetic variants and ACT were identified. These studies examined 84 different genes and 147 single nucleotide polymorphisms. Meta-analyses showed 3 risk variants significantly increased the risk for ACT; namely ABCC2 rs8187710 (pooled odds ratio: 2.20; 95% CI: 1.36–3.54), CYBA rs4673 (1.55; 1.05–2.30) and RAC2 rs13058338 (1.79; 1.27–2.52). The current evidence remains unclear on the potential role of pharmacogenomic screening prior to anthracycline therapy. Further research is needed to improve the diagnostic and prognostic role in predicting ACT.

show abstract

“…Nevertheless, this pattern of metastatic angiosarcoma leading to death in patients with angiosarcomatous differentiation of a primary MPNST has been documented in prior case studies . While gross total excision is the definitive treatment for both MPNST and angiosarcoma, in the latter malignancy there are data showing some benefit with chemotherapy, specifically in the setting of metastatic disease . Therefore, early identification of an angiosarcomatous component in a tumor of an NF1 patient should prompt a meticulous search for evidence of metastatic disease, which if found may alter the patient's treatment plan.…”

Section: Discussionmentioning

confidence: 98%

Metastatic angiosarcoma arising in malignant peripheral nerve sheath tumor in a young patient with neurofibromatosis type 1

Winters

Black

Cost

2017

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Neurofibromatosis type 1 (NF1) is a cancer predisposition syndrome with an incidence of approximately one in 3,000 and a lifetime risk of malignancy estimated at 8-13%. Here, we report the case of a patient with NF1 who developed synchronous malignant peripheral nerve sheath tumors, one with a focus of angiosarcoma. He succumbed to metastatic angiosarcoma despite local resection and adjuvant chemotherapy. This case highlights the need for monitoring for malignancy in NF1 patients, the risks of sampling error during tumor biopsy, and the clinical decision - making involved in choosing a therapeutic plan for a patient with multiple simultaneous malignancies.

show abstract

First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: Pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials

Cited by 95 publications

References 35 publications

New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype

New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype

Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis

Metastatic angiosarcoma arising in malignant peripheral nerve sheath tumor in a young patient with neurofibromatosis type 1

Contact Info

Product

Resources

About